PT Journal
AU Jirasek, P
   Jusku, A
   Simanek, V
   Frankova, J
   Storch, J
   Vacek, J
TI Cannabidiol and periodontal inflammatory disease: A critical assessment
SO Biomedical papers
PY 2022
BP 155
EP 160
VL 166
IS 2
DI 10.5507/bp.2022.012
DE cannabidiol; endocannabinoid system; CB1/2 receptors; microbial colonisation; bacterial virulence; immune system; gingivitis; periodontitis
AB Cannabidiol (CBD), a non-psychotropic cannabinoid produced by the genus Cannabis, is a phytoceutical that activates the endocannabinoid system (ECS) through binding to CB1 and CB2 receptors. The ECS is involved in cellular homeostasis and regulates metabolic processes in virtually all mammalian tissues. Published studies on CBD focus, inter alia, on its use in prophylaxis and as an anti-inflammatory agent. Here the authors present a critical assessment of the effects of CBD on inflammatory periodontal diseases caused by bacterial virulence factors, and evaluate critically the possible benefits and drawbacks of CBD use in dentistry. Particular attention is paid to the interaction of CBD with microbially colonized oral tissues, the inflammatory response in relation to the immune response, and the destruction/regeneration of hard and soft tissues of the periodontium.
ER